_best-practices-for-topical-generic-product-development-amp-anda-submissionsession-3-closing-remarks-preview-1.jpg "Best Practices for Topical Generic Product Development & ANDA Submission–Session 3, Closing Remarks from anda approval timeline Video Screenshot Preview 1")
Gallery_best-practices-for-topical-generic-product-development-amp-anda-submissionsession-3-closing-remarks-preview-3.jpg "Best Practices for Topical Generic Product Development & ANDA Submission–Session 3, Closing Remarks from anda approval timeline Video Screenshot Preview 3")
Gallery_best-practices-for-topical-generic-product-development-amp-anda-submissionsession-3-closing-remarks-preview-hqdefault.jpg "Best Practices for Topical Generic Product Development & ANDA Submission–Session 3, Closing Remarks from anda approval timeline Video Screenshot Preview hqdefault")
GalleryPlay Video:
(Note: The default playback of the video is HD VERSION. If your browser is buffering the video slowly, please play the REGULAR MP4 VERSION or Open The Video below for better experience. Thank you!)
Jump To Video Parts
⏲ Duration: 58 minutes 5 seconds
👁 View: 284 times
Play Audio:👁 View: 284 times
Description:
U.S. Food and Drug Administration
U.S. Food and Drug Administration
Share with your friends:
Whatsapp | Viber | Telegram | Line | SMS
Email | Twitter | Reddit | Tumblr | Pinterest
Related Videos
_patent-dispute-and-best-practices-for-505b2-and-anda-applicants-panel-discussion.webp "U.S. Food and Drug Administration")
⏲ 18 minutes 34 seconds 👁 612
_the-generic-drug-approval-process.webp "Alliance for Patient Access")
_anda-program-performance-review-and-tips-8of16-generic-drugs-forum-2020.webp "U.S. Food and Drug Administration")
⏲ 38 minutes 23 seconds 👁 684
_post-approval-considerations-for-changes-to-manufacturing-process-and-facilities-redi-2020.webp "U.S. Food and Drug Administration")
⏲ 28 minutes 11 seconds 👁 5.7K
_para-four-filing-procedure-and-180-days-exclusivity.webp "Pharma Learners")
_drug-master-files-dmfs-from-an-anda-perspective-7of28-generic-drugs-forum-apr-3-4-2019.webp "U.S. Food and Drug Administration")
⏲ 42 minutes 28 seconds 👁 873
_electronic-submission-of-an-anda-application-and-study-data-7of16-generic-drugs-forum-2020.webp "U.S. Food and Drug Administration")
⏲ 1 hour 5 minutes 31 seconds 👁 2K
_pre-anda-meeting-or-controlled-correspondence-4of28-generic-drugs-forum-apr-3-4-2019.webp "U.S. Food and Drug Administration")
⏲ 19 minutes 49 seconds 👁 505
_patent-dispute-and-best-practices-for-505b2-and-anda-applicants-panel-discussion.jpg)
_the-generic-drug-approval-process.jpg)
_anda-program-performance-review-and-tips-8of16-generic-drugs-forum-2020.jpg)
_post-approval-considerations-for-changes-to-manufacturing-process-and-facilities-redi-2020.jpg)
_para-four-filing-procedure-and-180-days-exclusivity.jpg)
_drug-master-files-dmfs-from-an-anda-perspective-7of28-generic-drugs-forum-apr-3-4-2019.jpg)
_electronic-submission-of-an-anda-application-and-study-data-7of16-generic-drugs-forum-2020.jpg)
_pre-anda-meeting-or-controlled-correspondence-4of28-generic-drugs-forum-apr-3-4-2019.jpg)
![[+]](/images/menu.gif){kind=small}